Treasury Proposal Targets China Biotech Stakes and Joint Ventures

The U.S. Treasury Department has added biotechnology as a new regulated sector under proposed rules for the Comprehensive Outbound Investment framework, according to Finance. The report says the proposal addresses Chinese biotechnology equity stakes and joint ventures, while new drug licensing receives different treatment.

Biotechnology added to proposed framework

Finance reports that biotechnology is included as a new regulated sector in the Treasury Department’s proposed rules for the Comprehensive Outbound Investment framework. The development places biotechnology alongside the investment activities addressed by the proposal.

The reported policy focus is on Chinese biotech equity stakes and joint ventures. Those structures are specifically identified in Finance’s headline as targets of the Treasury push to restrict activity under the proposed framework.

Equity stakes and joint ventures in focus

For pharmaceutical and biotechnology sales professionals, the report centers on partnership structures rather than a single product or company announcement. Finance identifies equity stakes and joint ventures as the forms of China-related biotechnology activity at issue in the Treasury proposal.

The Treasury action remains a proposed rule, according to Finance. The report describes biotechnology as newly added to the regulated sectors covered by the proposed Comprehensive Outbound Investment rules.

New drug licensing treated differently

Finance reports that new drug licensing gets a pass. This treatment distinguishes new drug licensing from the Chinese biotech equity stakes and joint ventures highlighted in the report.

The distinction is central to the reported proposal: biotechnology is named as a regulated sector, Chinese equity stakes and joint ventures are described as subject to restriction, and new drug licensing is described as receiving a pass. Finance attributes these details to the U.S. Treasury Department’s proposed rules.

Teams working across biopharma partnerships can track the proposal’s treatment of investment, joint-venture, and licensing structures as described by Finance.